KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oscar Health (OSCR) Current Deferred Revenue (2020 - 2025)

Oscar Health's Current Deferred Revenue history spans 6 years, with the latest figure at $166.2 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 123.42% year-over-year to $166.2 million; the TTM value through Dec 2025 reached $166.2 million, up 123.42%, while the annual FY2025 figure was $166.2 million, 123.42% up from the prior year.
  • Current Deferred Revenue reached $166.2 million in Q4 2025 per OSCR's latest filing, up from $77.1 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $166.2 million in Q4 2025 to a low of $56.2 million in Q3 2021.
  • Average Current Deferred Revenue over 5 years is $75.1 million, with a median of $72.3 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: decreased 17.93% in 2024, then soared 123.42% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $75.0 million in 2021, then grew by 5.27% to $79.0 million in 2022, then decreased by 16.56% to $65.9 million in 2023, then increased by 12.85% to $74.4 million in 2024, then skyrocketed by 123.42% to $166.2 million in 2025.
  • Per Business Quant, the three most recent readings for OSCR's Current Deferred Revenue are $166.2 million (Q4 2025), $77.1 million (Q3 2025), and $69.5 million (Q2 2025).